Skip Nav Destination
1-12 of 12
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study
Michael Khodadoust, MD PhD, Alain H. Rook, MD, Pierluigi Porcu, MD, Francine M. Foss, MD, Alison J. Moskowitz, MD, Andrei R Shustov, MD, Satish Shanbhag, MBBS, MPH, Lubomir Sokol, MD PhD, Richard Shine, PharmD, Steven P Fling, PhD, Shufeng Li, MS, Ziba Rabhar, Jinah Kim, MD PhD, Yi Yang, Jennifer Yearley, DVM, PhD, Elliot Keith Chartash, MD, Steven M. Townson, PhD, Priyanka B Subrahmanyam, PhD, Holden Maecker, PhD, Ash A. Alizadeh, MD PhD, Julia Dai, MD, Steven M Horwitz, MD, Elad Sharon, MD MPH, Holbrook Kohrt, MD, Martin A Cheever, MD, Youn Kim, MD
Blood (2016) 128 (22): 181.
First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results
Martine Bagot, MD, Pierluigi Porcu, MD, Caroline Ram-Wolff, MD, Michael Khodadoust, MD PhD, Maxime Battistella, MD, Anne Marie-Cardine, PhD, Steve Mathieu, MD, Maarten H. Vermeer, MD PhD, Sean Whittaker, MB, ChB, FRCP, MD, Madeleine Duvic, MD, Armand Bensussan, PhD, Carine Paturel, PhD, Cecile Bonnafous, PhD, Nicolas Thonnart, Agnes Widemann, PharmD, Cecile Bonin, PharmD, Helene Sicard, PhD, Christine Paiva, Korinna Pilz, MD, Youn Kim, MD
Blood (2016) 128 (22): 1826.
Pralatrexate Is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial.
Steven M. Horwitz, MD, Madeleine Duvic, MD, Youn Kim, MD, Jasmine M Zain, MD, Mary Jo Lechowicz, MD, Patricia Myskowski, MD, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD
Blood (2009) 114 (22): 919.
Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results of a Multi-Center Dose-Finding Trial.
Steven M. Horwitz, MD, Madeleine Duvic, MD, Youn Kim, MD, Jasmine M. Zain, MD, Mary Jo Lechowicz, MD, Patricia Myskowski, MD, Hanna Weissbrot, Danielle Wright, Lacey Chance, Tony Koutsoukos, Pablo Cagnoni, MD, Michael Saunders, MD, Owen A. O’Connor, MD, PhD
Blood (2008) 112 (11): 1569.
Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study
Youn Kim, MD, Sean Whittaker, MD, FRCP, Marie France Demierre, MD, Alain H Rook, MD, Adam Lerner, MD, Madeleine Duvic, MD, Sunil Reddy, MD, Ellen J Kim, MD, Tadeusz Robak, MD, Jürgen C Becker, MD, Alexey Samtsov, MD, William McCulloch, MB, FRCP, Archibald G Prentice, MBChB, FRCP, FRCPath
Blood (2008) 112 (11): 263.
Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Clinical and Molecular Characterization of a Subset with Worse Outcome.
Denise Woo, MD, Chris Jones, MD, Monique Vanoli-Storz, MD, Sabine Kohler, MD, Sunil Reddy, MD, Ranjana Advani, MD, Richard Hoppe, MD, Youn Kim, MD
Blood (2007) 110 (11): 3573.
Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study.
Blood (2007) 110 (11): 122.
Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.
Madeleine Duvic, MD, Youn Kim, MD, Sunil Reddy, MD, Andres Forero-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie Worobec, MD, Neil Korman, MD, Timothy Kuzel, MD, Kimberly Bohjanen, MD, Karen Flessland, Jeremy Barton, MD, Eric Sievers, MD
Blood (2006) 108 (11): 2733.
Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas.
Wei Yun Z. Ai, MD, PhD, Youn Kim, MD, Richard T. Hoppe, MD, Sumit Shah, Bsc, Sandra J. Horning, MD, Robert Tibshirani, PhD, Ronald Levy, MD
Blood (2006) 108 (11): 2716.
Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.
Blood (2006) 108 (11): 2467.
Immunoregulatory Effects of Allogeneic Mixed Chimerism Induced by T-Cell Depleted, Nonmyeloablative Bone Marrow Transplantation on Chronic Inflammatory Arthritis and Autoimmunity Developed in Interleukin-1 Receptor Antagonist-Deficient Mice.
Seok-Goo Cho, MD, PhD, Min-Chung Park, PhD, So-Youn Min, PhD, Young-Gyu Cho, PhD, Seok Lee, MD, PhD, Mi-La Cho, PhD, Hong-Seok Chang, MD, Jong-Wook Lee, MD, Woo-Sung Min, MD, Ho-Youn Kim, MD, Chun-Choo Kim, MD
Blood (2005) 106 (11): 1277.
Youn Kim, MD, Michael Girardi, MD, Madeline Duvic, MD, Timothy Kuzel, MD, Alain Rook, MD, Brian Link, MD, Lauren Pinter-Brown, MD, Carol Comerci, Sonja McAuley, Tess Schmalbach, MD
Blood (2004) 104 (11): 743.